Group Gp Lp Column III Buys 2,562 Shares of Surrozen (NASDAQ:SRZN) Stock

Surrozen, Inc. (NASDAQ:SRZN) major shareholder Group Gp Lp Column III purchased 2,562 shares of the business’s stock in a transaction on Friday, January 16th. The shares were bought at an average cost of $20.00 per share, with a total value of $51,240.00. Following the acquisition, the insider directly owned 1,007,090 shares of the company’s stock, valued at $20,141,800. This trade represents a 0.26% increase in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Group Gp Lp Column III also recently made the following trade(s):

• On Tuesday, January 20th, Group Gp Lp Column III purchased 18,052 shares of Surrozen stock. The stock was purchased at an average price of $19.60 per share, with a total value of $353,819.20.
• On Thursday, January 15th, Group Gp Lp Column III purchased 11,893 shares of Surrozen stock. The stock was acquired at an average price of $19.89 per share, with a total value of $236,551.77.
• On Wednesday, January 14th, Group Gp Lp Column III acquired 5,523 shares of Surrozen stock. The shares were bought at an average cost of $19.99 per share, with a total value of $110,404.77.
• On Tuesday, January 13th, Group Gp Lp Column III bought 12,470 shares of Surrozen stock. The shares were bought at an average price of $19.80 per share, with a total value of $246,906.00.
• On Tuesday, January 6th, Group Gp Lp Column III purchased 15,100 shares of Surrozen stock. The stock was bought at an average price of $19.89 per share, for a total transaction of $300,339.00.
• On Friday, December 5th, Group Gp Lp Column III purchased 30,884 shares of Surrozen stock. The stock was bought at an average price of $19.54 per share, for a total transaction of $603,473.36.
• On Thursday, December 4th, Group Gp Lp Column III acquired 5,266 shares of Surrozen stock. The shares were bought at an average cost of $17.35 per share, with a total value of $91,365.10.
• On Thursday, November 13th, Group Gp Lp Column III acquired 315,457 shares of Surrozen stock. The shares were purchased at an average price of $12.65 per share, with a total value of $3,990,531.05.

Surrozen Price Performance

Shares of SRZN stock traded down $2.02 during trading hours on Tuesday, hitting $17.98. The stock had a trading volume of 62,608 shares, compared to its average volume of 59,333. The stock has a market capitalization of $154.09 million, a price-to-earnings ratio of -0.80 and a beta of 0.58. Surrozen, Inc. has a one year low of $5.90 and a one year high of $24.94. The stock’s 50-day moving average price is $18.98 and its two-hundred day moving average price is $14.13.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings results on Friday, November 7th. The company reported ($3.61) EPS for the quarter, missing analysts’ consensus estimates of ($1.17) by ($2.44). The firm had revenue of $0.98 million for the quarter. Surrozen had a negative net margin of 2,909.10% and a negative return on equity of 4,055.04%. As a group, equities research analysts predict that Surrozen, Inc. will post -8.49 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SRZN has been the topic of several research reports. Wall Street Zen upgraded shares of Surrozen to a “sell” rating in a research report on Friday, November 28th. Lifesci Capital raised shares of Surrozen to a “strong-buy” rating in a research note on Thursday, November 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $32.00.

Institutional Investors Weigh In On Surrozen

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Citadel Advisors LLC boosted its position in Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after buying an additional 3,424 shares during the period. Geode Capital Management LLC raised its stake in shares of Surrozen by 22.6% during the second quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock valued at $277,000 after acquiring an additional 5,702 shares in the last quarter. Acuta Capital Partners LLC boosted its holdings in shares of Surrozen by 5.0% in the third quarter. Acuta Capital Partners LLC now owns 178,415 shares of the company’s stock valued at $2,299,000 after purchasing an additional 8,415 shares during the period. Stonepine Capital Management LLC grew its stake in Surrozen by 7.1% in the second quarter. Stonepine Capital Management LLC now owns 306,029 shares of the company’s stock worth $2,736,000 after purchasing an additional 20,247 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in Surrozen by 21.7% in the third quarter. Vanguard Group Inc. now owns 266,418 shares of the company’s stock worth $3,433,000 after purchasing an additional 47,468 shares in the last quarter. Institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.